Verrica Pharmaceuticals (NASDAQ:VRCA) Target Lowered by Needham & Company LLC to $17.00

0
25
Goldene Symbolfiguren auf Finanzzeitung

Verrica Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Verrica Pharmaceuticals stock Target Lowered by   Needham & Company LLC on 6/30/2020. In a note to investors, the firm issued a new target price of $17.00. The analysts previously had $20.00 target price. Needham & Company LLC’s price target would indicate a potential upside of 20.82% from the stock’s previous close.

Shares of Verrica Pharmaceuticals traded down -$3.52 on Tuesday, reaching $10.55. 175182 shares of the stock traded hands, compared to its average volume of 63735. Shares of were trading at $10.55 on Tuesday. The firm’s 50 day moving average is $$11.82 and its 200 day moving average is $13.19.Verrica Pharmaceuticals  has a 12 month low of $10.29 and a 12 month high of $18.67. While on yearly highs and lows, Verrica Pharmaceuticals today has traded high as $11.33 and has touched $10.29 on the downward trend.

Verrica Pharmaceuticals Earnings and What to expect: 

Verrica Pharmaceuticals last announced its quarterly earnings data on May 7th, 2020. The reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.01. Verrica Pharmaceuticals has generated ($1.13) earnings per share over the last year. Verrica Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 5th, 2020 based off prior year’s report dates.

Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($2.32) to ($1.79) per share. The P/E ratio of Verrica Pharmaceuticals is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Verrica Pharmaceuticals is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Verrica Pharmaceuticals has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 40.60%
  • On 10/10/2019 Director Paul B Manning Buy 20,886 at average share price of $15.08 which equates to $314,960.88 in money value.
  • On 9/9/2019 Major Shareholder Matt Davidson Sell 19,314 at average price of  $10.89 with total value of : Not Data Available
  • On 8/29/2019 Major Shareholder Matt Davidson Sell 2,688 at average price of  $10.16 with total value of : $27,310.08
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Verrica Pharmaceuticals

  • 6/30/2020 – Verrica Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $24.00 to $18.00. They now have a “buy” rating on the stock.
  • 6/25/2020 – Verrica Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating.
  • 6/24/2020 – Verrica Pharmaceuticals is now covered by analysts at Northland Securities. They set an “outperform” rating and a $21.00 price target on the stock.
  • 6/23/2020 – Verrica Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • See More Analyst Rating at: RATING

Other rating updates by Needham & Company LLC: 

  • 6/30/2020 – Intercept Pharmaceuticals had its price target lowered by analysts at Needham & Company LLC from $150.00 to $100.00. They now have a “buy” rating on the stock.
  • 6/30/2020 – Gilead Sciences had its “hold” rating re-affirmed by analysts at Needham & Company LLC.
  • 6/30/2020 – Xilinx had its “hold” rating re-affirmed by analysts at Needham & Company LLC.
  • 6/30/2020 – Seattle Genetics had its price target raised by analysts at Needham & Company LLC from $163.00 to $188.00. They now have a “buy” rating on the stock.
  • See More Analyst Rating at: RATING

Verrica Pharmaceuticals (NASDAQ:VRCA) Moving Average Technical Analysis

5 day Moving Average is $$13.44 And 5 day price change is -$4.62 (-30.56%)  with average volume for 5 day average is 131,841. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $12.84 and 20 day price change is -$1.04 (-9.01%) and average 20 day moving volume is 75,730. 50 day moving average is $11.82  and 50 day price change is -$0.08 ( -0.76%)  and with average volume for 50 days is : 61,128. 200 day moving average is $13.19  and 200 day price change is -$3.63 (-25.69%)  and with average volume for 200 days is : 69,880.

See More Analyst Rating at: RATING